ArticleHealth science reports2025
Transformative Advances in Continuous Glucose Monitoring and the Impact of FDA Over-the-Counter Approval on Diabetes Care.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Expanding continuous glucose monitoring's potential from real-time safety to lifestyle support in type 1 diabetes exercise: a proof-of-concept study among adults with low baseline exercise levels.Human factors in healthcare · 2026Article
- GVC-Calc enables large-scale analysis of continuous glucose monitoring data.Nature metabolism · 2026Article
- The Relationship between Hemoglobin A1c and the Glucose Management Indicator and Glucose Metrics in Children and Adolescents with Type 1 Diabetes Mellitus Using Automated Insulin Delivery SystemsJournal of clinical research in pediatric endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Continuous glucose monitoring (CGM) has significantly advanced diabetes management, evolving from early glucose testing methods to modern, FDA-approved systems. Despite its benefits, challenges related to data security, affordability, and awareness of CGM devices remain. Aim: This article explores the historical development, current advancements, and ongoing challenges of CGM systems in diabetes management. It aims to provide insights into how these technologies have transformed patient care and highlight areas needing further improvement. Methods: A comprehensive literature review was conducted, focusing on advancements in CGM technology. Sources included PubMed, Google Scholar, and recent guidelines and reviews on CGM systems and their impact on diabetes management. Results: The evolution from the Dextrostix test strip to modern CGM systems, including over-the-counter devices, has enhanced glucose monitoring and patient outcomes. Recent innovations, such as machine learning models for predicting glucose fluctuations, promise to improve diabetes management. However, issues like data security and device accessibility persist. Conclusion: To maximize the benefits of CGM systems, addressing data security, improving affordability, and increasing awareness of CGM devices are crucial. Continued advancements in CGM technology and supportive policies are essential for enhancing diabetes care and patient outcomes globally.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.